Credit Suisse AG lifted its position in Stoke Therapeutics, Inc. (NASDAQ:STOK) by 80.8% in the 4th quarter, Holdings Channel reports. The fund owned 13,165 shares of the company’s stock after acquiring an additional 5,884 shares during the quarter. Credit Suisse AG’s holdings in Stoke Therapeutics were worth $815,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in STOK. BlackRock Inc. boosted its position in shares of Stoke Therapeutics by 34.3% during the fourth quarter. BlackRock Inc. now owns 1,660,060 shares of the company’s stock valued at $102,807,000 after purchasing an additional 423,844 shares in the last quarter. Northern Trust Corp lifted its position in Stoke Therapeutics by 2.8% during the fourth quarter. Northern Trust Corp now owns 199,970 shares of the company’s stock valued at $12,384,000 after buying an additional 5,413 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in shares of Stoke Therapeutics by 46.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 93,759 shares of the company’s stock valued at $3,140,000 after buying an additional 29,868 shares in the last quarter. Victory Capital Management Inc. grew its position in shares of Stoke Therapeutics by 13.8% in the 4th quarter. Victory Capital Management Inc. now owns 76,928 shares of the company’s stock worth $4,764,000 after buying an additional 9,352 shares during the period. Finally, Bank of New York Mellon Corp grew its position in shares of Stoke Therapeutics by 10.8% in the 4th quarter. Bank of New York Mellon Corp now owns 54,235 shares of the company’s stock worth $3,358,000 after buying an additional 5,281 shares during the period.
In other Stoke Therapeutics news, CFO Stephen J. Tulipano sold 30,000 shares of Stoke Therapeutics stock in a transaction that occurred on Tuesday, February 23rd. The shares were sold at an average price of $58.86, for a total value of $1,765,800.00. Also, Director Arthur Tzianabos sold 10,000 shares of the firm’s stock in a transaction on Friday, February 19th. The stock was sold at an average price of $60.67, for a total value of $606,700.00. Following the completion of the transaction, the director now owns 10,000 shares in the company, valued at $606,700. The disclosure for this sale can be found here. Company insiders own 54.60% of the company’s stock.
Stoke Therapeutics (NASDAQ:STOK) last issued its earnings results on Monday, March 8th. The company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.01). Equities research analysts predict that Stoke Therapeutics, Inc. will post -1.58 earnings per share for the current year.
Several equities research analysts recently commented on the stock. Wedbush lowered shares of Stoke Therapeutics from an “outperform” rating to a “neutral” rating in a research note on Wednesday, February 10th. Credit Suisse Group boosted their price target on Stoke Therapeutics from $49.00 to $58.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 16th. Needham & Company LLC raised their price objective on Stoke Therapeutics from $56.00 to $65.00 and gave the company a “buy” rating in a research report on Thursday, January 14th. Zacks Investment Research downgraded Stoke Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, March 13th. Finally, HC Wainwright restated a “buy” rating and set a $70.00 price target on shares of Stoke Therapeutics in a report on Tuesday, December 15th. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Stoke Therapeutics has a consensus rating of “Buy” and a consensus target price of $65.00.
Stoke Therapeutics Profile
Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops novel antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001 used to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc has a partnership with Invitae Corporation to offer genetic testing.
Recommended Story: Cost of Equity
Want to see what other hedge funds are holding STOK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stoke Therapeutics, Inc. (NASDAQ:STOK).
Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.